ClinicalTrials.gg
CompletedNCT05529849Updated Feb 21, 2024

A Study to Assess the Safety, Tolerability and Pharmacokinetics of TCMCB07 in Single and Multiple Ascending Doses in Health Subjects

A Phase 1 interventional study of TCMCB07 and Placebo in Cachexia, sponsored by Endevica Bio. Completed at 1 site in United States. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-02-21.

Sponsored by Endevica Bio · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Primary completion was Dec 2022, 3 years 11 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
76
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 95 studies in Cachexia with a site in United States — 9 open to participants now, 11 under way, 2 of them phase 3. Cachexia · United States.

Enrollment
24th of 72
76 · median 51
Started
2022
with 4 others
Phase 1
21 of 95
2 open now
Registered
84th of 95
by date

Among the 95 studies in Cachexia with a site in United States, this one is the 24th largest by enrollment of the 72 interventional ones that give a count, is one of 5 that started in 2022, is one of 21 in phase 1, and was the 84th registered.

Cachexia

331 studies on the registry are indexed under Cachexia; 74 are open to participants now.

Browse Cachexia studies →

Open to participants now

9 of the 95 studies in Cachexia with a site in United States are open now. Recruiting first, the newest first:

4 more — sign in →

All 9 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 55 Cachexia studies recruiting now, 32 (58%) set no upper age limit and 14 (25%) stop at 75 or younger; 7 take children under 18; 16 take healthy volunteers.

This study: 18 Years to 55 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 95 studies in Cachexia with a site in United States, or all of them as a file.
02

Study summary

This study will test an experimental drug named TCMCB07 for the treatment of cancer cachexia. Cachexia is a syndrome characterized by weight loss, anorexia, weakness or lack of energy, and anemia. Cachexia occurs in many cancers, usually at the advanced stages of disease.

03

Conditions studied

  • Cachexia

Browse trials for

04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Healthy males and females (WONCBP), aged 18 to 55 years inclusive, at time of signing .
  • 18.0 to 30.0 kg/m2 as measured at Screening or, if outside this range, considered not by the investigator.
  • Weight ≥ 50 kg at Screening

Exclusion criteria

Exclusion Criteria:

  • Serious adverse reaction or serious known to melanocortins or polyethylene glycol.
  • Evidence of current severe acute respiratory syndrome coronavirus 2 infection.
  • abnormal clinical chemistry, hematology, or urinalysis as judged by the investigator.
  • Subjects who have received any IP in a clinical research study within 5 half-lives or within 30 days prior to first dose. However, in no event shall the time between last receipt of IP and first dose be less than 30 days.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
76 participants (actual)

Study arms

  • Experimental
    TCMCB07

    once daily subcutaneous injection

    Drug: TCMCB07

  • Placebo comparator
    Placebo

    once daily subcutaneous injection

    Drug: Placebo

Interventions

  • DrugTCMCB07

    Subcutaneous injection of TCMCB07

  • DrugPlacebo

    Matching subcutaneous placebo

06

What researchers measure

Primary outcomes

  1. Number of people with an Adverse Event Assessment

    Adverse Event monitoring

    Time frame: 6 Months

  2. Number of participants with abnormal vital signs

    Assessment of vital signs

    Time frame: 6 Months

  3. Number of people with abnormal laboratory test results

    Analysis of clinical chemistry, hematology, and urinalysis

    Time frame: 6 Months

  4. Number of people with abnormal Electrocardiograms

    12-lead ECGs will be used and an assessment of any clinically significant abnormality from baseline will be reported as an AE

    Time frame: 6 Months

  5. Number of people with abnormal physical examinations

    Physical and injection site examination

    Time frame: 6 Months

Secondary outcomes

  1. Peak Plasma Concentration (Cmax)

    Non-compartmental techniques will be employed to obtain estimates of cmax

    Time frame: 6 Months

  2. Area under the plasma concentration versus time curve (AUC)

    Non-compartmental techniques will be employed to obtain estimates of AUC

    Time frame: 6 months

07

Study locations

1 site
  • Quotient Sciences -- Miami, Inc.
    Miami, Florida 33126, United States
08

References and documents

Related links

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jul 2022 to primary completion in Dec 2022, 5 months.

Of 21 phase 1 interventional studies under Cachexia, half reached primary completion within 11 months of starting (the median), counting those still running; a quarter within 8 and three quarters within 25. This study's 5 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 28, 2022
First posted
Sep 7, 2022
StartActual
Jul 12, 2022
Primary completionActual
Dec 12, 2022
CompletionActual
Feb 20, 2023
Last update
Feb 21, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 21, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05529849
Lead sponsor
Endevica Bio
Responsible party
Sponsor
First posted
Sep 7, 2022
Start date
Jul 12, 2022
Primary completion
Dec 12, 2022
Completion
Feb 20, 2023
Last update
Feb 21, 2024

Study contacts

Maria Bermudez, MD, CPI
principal investigator · Quotient Sciences

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion